Irinotecan as a second-line monotherapy for small cell lung cancer.

  title={Irinotecan as a second-line monotherapy for small cell lung cancer.},
  author={Alper Sevinç and Mehmet Emin Kalender and Mustafa Altinbaş and Metin Ozkan and Mustafa Dikilitaş and Celalettin Camci},
  journal={Asian Pacific journal of cancer prevention : APJCP},
  volume={12 4},
OBJECTIVES The present study was designed to investigate the efficacy of irinotecan monotherapy as a second-line treatment for small cell lung cancers (SCLCs). METHODS Irinotecan monotherapy was administered to 46 SCLC patients who were previously undergone cisplatin based chemotherapy protocols. Response to treatment, time to progression (TTP), overall survival rates and adverse events associated with irinotecan monotherapy (300mg/m2; total 153 cycles; mean 3.78 ∓ 1.98) were determined… CONTINUE READING

Similar Papers

Loading similar papers…